Private-equity backed Stada aims to launch an initial public offering this fall following a postponement this past spring, joining the scattering of companies queuing up to list before year-end.

The German pharmaceutical company delayed plans to go public in April, citing geopolitical uncertainty and market volatility. Other companies like StubHub and Klarna also delayed IPOs earlier this year due to market volatility stemming from U.S. President Trump’s tariff policies.